Toshiro Miwa

508 citations

43 papers · 362 indexed · h-index 11

Co-authors: Minehiko Inomata Ryuji Hayashi Seisuke Okazawa Kazuyuki Tobe Shoko Matsui Kenta Kambara Shingo Imanishi Kensuke Suzuki
Topics: Lung Cancer Treatments and Mutations (13 papers)Lung Cancer Research Studies (12 papers)Cancer Immunotherapy and Biomarkers (10 papers)
Cited by: Geriatrics and Gerontology Oncology Physiology
Journals: Journal of Clinical Oncology Scientific Reports Biochemical and Biophysical Research Communications
Partner nations: Japan United States

In The Last Decade

Toshiro Miwa

39 papers receiving 358 citations

Peers

Countries citing papers authored by Toshiro Miwa

Since Specialization

Citations

This map shows the geographic impact of Toshiro Miwa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshiro Miwa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshiro Miwa more than expected).

Fields of papers citing papers by Toshiro Miwa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshiro Miwa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshiro Miwa. The network helps show where Toshiro Miwa may publish in the future.

Co-authorship network of co-authors of Toshiro Miwa

This figure shows the co-authorship network connecting the top 25 collaborators of Toshiro Miwa. A scholar is included among the top collaborators of Toshiro Miwa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshiro Miwa. Toshiro Miwa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multicenter Retrospective Analysis of Pulmonary Sarcomatoid Carcinoma Clinically Diagnosed Using Small Biopsy Specimens 2025 ·Cancer Diagnosis & Prognosis ·Minehiko Inomata,(unknown),Tomomi Ichikawa,(unknown),(unknown),(unknown),Naoki Takata,(unknown),(unknown),(unknown),(unknown),Seisuke Okazawa,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Hirokazu Taniguchi	0
2	Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer 2023 ·Scientific Reports ·Minehiko Inomata,(unknown),Naoki Takata,(unknown),(unknown),(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	10
3	Lung Cancer Wherein Durvalumab Induced Both Anti-CRMP-5 Antibody-related Paraneoplastic Neurological Syndromes and Neurological Adverse Events 2023 ·Internal Medicine ·(unknown),Kousuke Baba,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Toshiro Miwa,Keiko Tanaka,Yuji Nakatsuji	2
4	Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer 2022 ·Cancer Diagnosis & Prognosis ·Minehiko Inomata,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	7
5	Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression 2021 ·Cancer Diagnosis & Prognosis ·Minehiko Inomata,Naoki Takata,(unknown),(unknown),(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	4
6	Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors 2021 ·In Vivo ·(unknown),(unknown),Minehiko Inomata,(unknown),(unknown),Naoki Takata,(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Satoshi Nomura,Kazuyuki Tobe	5
7	Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer 2020 ·Tumori Journal ·(unknown),Naoki Takata,(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Minehiko Inomata	2
8	Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy 2020 ·Diagnostics ·Minehiko Inomata,(unknown),Naoki Takata,(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	13
9	Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor 2019 ·Anticancer Research ·Minehiko Inomata,(unknown),Seisuke Okazawa,Shingo Imanishi,(unknown),Kenta Kambara,(unknown),Hiroaki Tanaka,(unknown),(unknown),Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	26
10	Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy 2018 ·Pathology & Oncology Research ·Minehiko Inomata,(unknown),(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Tomomi Ichikawa,Shingo Imanishi,Tōru Yamada,Toshiro Miwa,Ryuji Hayashi,Kazuyuki Tobe	18
11	Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression 2017 ·Oncology and Therapy ·Minehiko Inomata,Hiroaki Tanaka,(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toru Yamada,Toshiro Miwa,Ryuji Hayashi,Kazuyuki Tobe	1
12	Relationship between Carnitine Pharmacokinetics and Fatigue in Patients Treated with Cisplatin-Containing Chemotherapy 2017 ·Oncology Research and Treatment ·(unknown),Kensuke Suzuki,Kenta Kambara,Minehiko Inomata,Seisuke Okazawa,Shinya Kajiura,Toshiro Miwa,(unknown),Tatsuhiko Kashii	4
13	Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer 2016 ·Anticancer Research ·Minehiko Inomata,(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Tōru Yamada,Toshiro Miwa,Ryuji Hayashi,Tatsuhiko Kashii,Shoko Matsui,Kazuyuki Tobe	8
14	Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib 2016 ·Molecular and Clinical Oncology ·Minehiko Inomata,Ryuji Hayashi,Hiroaki Tanaka,(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Tomomi Ichikawa,Tōru Yamada,Toshiro Miwa,Tatsuhiko Kashii,Shoko Matsui,Kazuyuki Tobe	18
15	Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib 2015 ·Molecular and Clinical Oncology ·Minehiko Inomata,Ryuji Hayashi,(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Kensuke Suzuki,Tomomi Ichikawa,Toru Yamada,Toshiro Miwa,Tatsuhiko Kashii,Shoko Matsui,Kazuyuki Tobe,Johji Imura	12
16	Relationship of the urine cortisol level with the performance status of patients with lung cancer: a retrospective study 2014 ·Supportive Care in Cancer ·Kensuke Suzuki,Tomomi Ichikawa,(unknown),(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Minehiko Inomata,Tōru Yamada,Toshiro Miwa,Shoko Matsui,Tatsuhiko Kashii,Hirokazu Taniguchi,Ryuji Hayashi,Kazuyuki Tobe	3
17	Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin‐induced mouse model of asthma 2012 ·Respirology ·Tomomi Ichikawa,Ryuji Hayashi,Kensuke Suzuki,Shingo Imanishi,Kenta Kambara,Seisuke Okazawa,Minehiko Inomata,Tōru Yamada,Yu Yamazaki,(unknown),Toshiro Miwa,Shoko Matsui,Isao Usui,Masaharu Urakaze,Yûji Matsuya,Masakiyo Sasahara,Kazuyuki Tobe	71
18	Cloning, bacterial expression, and unique structure of adenosylhomocysteine hydrolase-like protein 1, or inositol 1,4,5-triphosphate receptor-binding protein from mouse kidney 2008 ·Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics ·Tomoharu Gomi,Fusao Takusagawa,Mikio Nishizawa,Agussalim Bukhari,Isao Usui,Eiji Sugiyama,Hirofumi Taki,(unknown),Hiroyuki Hounoki,Toshiro Miwa,Kazuyuki Tobe,(unknown),Tetsuya Ishimoto,Hirofumi Ogawa,Hisashi Mori	8
19	Ionizing radiation suppresses FAP‐1 mRNA level in A549 cells via p53 activation 2006 ·FEBS Letters ·Tōru Yamada,Muneharu Maruyama,Tadashi Fujita,(unknown),(unknown),Yukio Kawagishi,(unknown),Ryuji Hayashi,Toshiro Miwa,(unknown),Shoko Matsui,Eiji Sugiyama,Masashi Kobayashi	5
20	[X-ray-negative endobronchial tuberculosis with persistent irritating cough that resulted in unpredicted mass infection]. 2003 ·PubMed ·Hirokazu Taniguchi,Kensuke Suzuki,(unknown),Hitoshi Abo,Toshiro Miwa,(unknown),(unknown),(unknown)	4

About Toshiro Miwa

Toshiro Miwa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology, having authored 43 papers that have together received 362 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). The work is most often cited by research in Geriatrics and Gerontology (60 citations), Oncology (163 citations) and Physiology (20 citations). Toshiro Miwa has collaborated with scholars based in Japan and United States. Frequent co-authors include Minehiko Inomata, Ryuji Hayashi, Seisuke Okazawa, Kazuyuki Tobe, Shoko Matsui, Kenta Kambara, Shingo Imanishi, Kensuke Suzuki, Tōru Yamada and Tatsuhiko Kashii. Their work appears in journals such as Journal of Clinical Oncology, Scientific Reports and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact